Overview
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Eligibility
Inclusion Criteria:
- right handed
Exclusion Criteria:
- pregnant or breast feeding
- past or current neurological disorder
- non-ADHD cause of cognitive impairment
- uncontrolled medical disorder
- head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
- having an adverse reaction to methylphenidate, or other stimulant medication
- having a contraindication to MRI
- current smoking